Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- How to Build a Winning Marketing Team
Philip Carrigan
Partner, Optia Partners
philip@optiapartners.com
August 30, 2010
- Takeda Considers Acquisition of Overseas Company: Mr Hasegawa
August 30, 2010
- Astellas Ties Up with UMN Pharma to Jointly Develop Flu Vaccines
August 30, 2010
- Korosho to Conduct Large-Scale Trial for Antipsychotics
August 30, 2010
- MTPC Transfers Kerlong to sanofi-aventis
August 30, 2010
- Towa: Direct Sales Ratio Up by More Than 10 Points
August 30, 2010
- Proper Use of Antidepressants Discussed: Symposium
August 30, 2010
- Pola to Comarket Teika's Bedsore Treatment Sorenurse
August 30, 2010
- Nippon Chemiphar: Generics Account for 64% of Total Sales
August 30, 2010
- PMDA Calls For Regular Lab Tests in Patients Treated with SASP
August 30, 2010
- R-Tech Ueno Terminates Licensing Agreement for Human Serum Albumin with MTPC
August 30, 2010
- Fuji Pharma: Generic Diagnostics Drive Business
August 30, 2010
- Immunotherapy for Renal Cell Carcinoma Approved as Advanced Therapy
August 30, 2010
- R-Tech Ueno Applies for Arbitration in Disputes with Takeda over Agreement on Amitiza
August 30, 2010
- Eli Lilly Discontinues Development of Semagacestat for AD
August 30, 2010
- Cervarix Adverse Events Reported from 37 Recipients
August 30, 2010
- Alfresa to Make Tampei Nakata Wholly-Owned Subsidiary
August 30, 2010
- IPSN, INCJ to Invest in IP Rights in 4 Fields
August 30, 2010
- JCQHC Calls For a Rest for MTX
August 30, 2010
- PI Forum to Promote Drug Discovery: Chairman Asano
August 30, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…